289 related articles for article (PubMed ID: 25676724)
21. [Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer].
Dong M; Li T; Chen J
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):116-120. PubMed ID: 29526179
[TBL] [Abstract][Full Text] [Related]
22. Targeted agents in the management of small cell lung cancer - present and future.
Srivastava R; Lebowicz Y; Jamil MO
Drugs Today (Barc); 2018 Aug; 54(8):479-488. PubMed ID: 30209442
[TBL] [Abstract][Full Text] [Related]
23. Approaching the increasing complexity of non-small cell lung cancer taxonomy.
Maugeri-Sacca M; Bartucci M; Pagliuca A; Patrizii M; Signore M; De Maria R
Curr Pharm Des; 2014; 20(24):3973-81. PubMed ID: 24138717
[TBL] [Abstract][Full Text] [Related]
24. Refining the treatment of NSCLC according to histological and molecular subtypes.
Thomas A; Liu SV; Subramaniam DS; Giaccone G
Nat Rev Clin Oncol; 2015 Sep; 12(9):511-26. PubMed ID: 25963091
[TBL] [Abstract][Full Text] [Related]
25. Pathway targets to explore in the treatment of non-small cell lung cancer.
Weiss GJ; Kingsley C
J Thorac Oncol; 2008 Nov; 3(11):1342-52. PubMed ID: 18978571
[TBL] [Abstract][Full Text] [Related]
26. Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
Codacci-Pisanelli G; Frati L; Mini E
J Chemother; 2011 Aug; 23(4):245-6. PubMed ID: 21803707
[No Abstract] [Full Text] [Related]
27. The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.
Harwood CA; Proby CM; Inman GJ; Leigh IM
Acta Derm Venereol; 2016 Jan; 96(1):3-16. PubMed ID: 26084328
[TBL] [Abstract][Full Text] [Related]
28. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
29. Personalized therapy on the horizon for squamous cell carcinoma of the lung.
Kim HS; Mitsudomi T; Soo RA; Cho BC
Lung Cancer; 2013 Jun; 80(3):249-55. PubMed ID: 23489560
[TBL] [Abstract][Full Text] [Related]
30. Current readings: Window-of-opportunity trials for thoracic malignancies.
Tsao AS
Semin Thorac Cardiovasc Surg; 2014; 26(4):323-30. PubMed ID: 25837547
[TBL] [Abstract][Full Text] [Related]
31. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
32. Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
Kuiper JL; Ronden MI; Becker A; Heideman DA; van Hengel P; Ylstra B; Thunnissen E; Smit EF
J Clin Pathol; 2015 Apr; 68(4):320-1. PubMed ID: 25661795
[No Abstract] [Full Text] [Related]
33. Onartuzumab in lung cancer: the fall of Icarus?
Rolfo C; Van Der Steen N; Pauwels P; Cappuzzo F
Expert Rev Anticancer Ther; 2015 May; 15(5):487-9. PubMed ID: 25818471
[TBL] [Abstract][Full Text] [Related]
34. Squamous cell lung cancer: from tumor genomics to cancer therapeutics.
Gandara DR; Hammerman PS; Sos ML; Lara PN; Hirsch FR
Clin Cancer Res; 2015 May; 21(10):2236-43. PubMed ID: 25979930
[TBL] [Abstract][Full Text] [Related]
35. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
Kruglyak KM; Lin E; Ong FS
Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
[TBL] [Abstract][Full Text] [Related]
36. Methodology of clinical trials in lung cancer.
Menis J; Besse B; Lacombe D
Chin Clin Oncol; 2015 Dec; 4(4):44. PubMed ID: 26730756
[TBL] [Abstract][Full Text] [Related]
37. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
Somer RA; Sherman E; Langer CJ
Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
[TBL] [Abstract][Full Text] [Related]
38. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
Sacher AG; Gandhi L
JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
[TBL] [Abstract][Full Text] [Related]
40. Second-line chemotherapy for non-small cell lung cancer.
Ruckdeschel JC
Chest; 2006 Apr; 129(4):840-2. PubMed ID: 16608927
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
